(RTTNews) – Cosmos Health Inc. (COSM), a diversified global healthcare company, disclosed its second‑quarter results, which showed a widened net loss driven by higher fair‑value expenses on convertible notes and increased interest costs, even though revenue rose 28% versus the prior year.
Cosmos, via its subsidiaries, operates across pharmaceutical distribution, branded generics, over‑the‑counter medicines, nutraceuticals, and healthcare products.
Second Quarter Results
For the quarter ended June 30, 2026, the net loss increased to $6.09 million, up from $2.83 million in the second quarter of 2025. Earnings per share stayed at $0.10 in both periods.
Adjusted net loss amounted to $1.69 million, compared with $1.59 million in Q2 2025, reflecting higher net interest expense.
The increase was driven by $2.65 million in non‑cash charges, comprising a $2.38 million loss from fair‑value changes on convertible notes, $0.40 million in non‑cash interest expense, and a $0.40 million loss on digital assets. Additional interest expense of $0.60 million also contributed.
Revenue increased 28.8% to $18.99 million, up from $14.74 million a year earlier, propelled by higher sales volumes across core segments. Adjusted revenue grew 31% to $19.32 million.
On an adjusted basis, EBITDA loss narrowed to $1.13 million from $1.31 million a year ago.
Clinical And Corporate Updates
Cosmos Health’s C‑Scrub Wash 4% met EN 12791 standards, enabling its rollout into hospital, surgical and professional healthcare channels. The firm also entered the animal health market after completing EN 1656 and EN 1657 testing on a veterinary formulation.
The company broadened its 18 Series nutraceutical platform in the United States, focusing on liver health, joint and inflammation support, cardiovascular health, men’s wellness, and healthy aging.
It advanced its CCX0722 weight‑management hydrogel patent to the United States, Europe, Australia and Canada. The firm has integrated AI into order management, warehousing and supply‑chain processes, expecting cost reductions of up to 30%.
Corporately, Cosmos Health signed an advisory agreement with the European Investment Bank for up to €25 million of potential financing for its R&D program, identified roughly $20 million of non‑core assets for possible sale, and signed a letter of intent to acquire Doc Pharma S.A.
The company also launched a $5 million share repurchase program slated to expire on December 31, 2026.
Cash Position
As of June 30, 2026, cash, cash equivalents and restricted cash totaled $2.44 million.
Stock Quote
Cosmos shares have traded in the $0.16‑$1.32 range over the past year.
The shares closed Wednesday at $0.19, a decline of 6.58%. In after‑hours trading, they fell 3.01% to $0.18.
Also Read
- Taiwan Semiconductor vs. ASML: Choosing the Superior Semiconductor Investment
- Colombia and Israel Establish Mutual Visa-Free Travel as Diplomatic Ties Rebuilt
- Asia Tech Briefing: Google’s China Manufacturing Shift, AI Chip Curbs, and Geopolitical Divides
- S&P 500 Surges 33% Post-Election: Why Midterm Volatility Shouldn’t Derail Your Portfolio
